Prevalence and the Risk Factors Associated with HIV-TB Co-Infection Among Clinic Attendees in Dots and Art Centres in Ibadan, Nigeria

Adeloye Adewale  Idowu; Ayinde Abayomi  Oluwasegun; Ohue Michael; Tope Gloria Olatunde-Aiyedun; Ogunode Niyi  Jacob

doi:10.17605/cajmns.v2i3.177

Adeloye Adewale Idowu University of Ontario institute of technology (Public Health)
Ayinde Abayomi Oluwasegun University of Ibadan (Public Health Epidemiology and Medical Statistics)
Ohue Michael APIN Public Health Initiatives
Tope Gloria Olatunde-Aiyedun University of Abuja
Ogunode Niyi Jacob University of Abuja

DOI: https://doi.org/10.17605/cajmns.v2i3.177

Keywords: TB/HIV Co-infection, Extra-vaginal intercourse, Antiretroviral Therapy (ART) Multidrug therapy (MDT)

Abstract

Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) co-infection form a very serious public health menace in Nigeria. Among patients confirmed to have been infected with either of the disease, co-infection with the other is highly prevalent. However, comprehensive studies focusing on the distributions and correlates of TB/HIV co-infections among Patients attending TB clinics in Ibadan are lacking in the literature. The objective of this study was to determine the prevalence and correlates of TB/HIV co-infection among patients suspected to be TB positive at various health facilities offering TB/HIV Collaboration Service (THCS) in Ibadan. A descriptive cross-sectional study was carried out among 500 TB/ HIV clinic attendees in Ibadan, Nigeria. A simple random sampling method was used to select 8 TB clinics in Ibadan from the list of all clinics offering THCS in Ibadan. An interviewer administered questionnaire was used to elicit information on TB/HIV status, risk factors and knowledge of HIV and TB from all participants who consented to be interviewed. Descriptive statistics, Chi-square test and logistic regression were used for data analysis at 5% level of significant. Mean age of the patients was 33.98±13.15 years. The overall prevalence of TB/HIV co-infection among the participants was found to be (41.6%). Prevalence of TB/HIV co-infection were highest (11.2% and 14.8%) among participants in age group 20-29 years and 30-39 years respectively. More females (25.2%) than males (16.4%) had been infected with TB/HIV co- infection. While the prevalence of TB/HIV co-infection were respectively 2.0%, 6.6% 18.4% and 14.6% among participants with no formal education, Primary education, Secondary education and Tertiary education, the prevalence was 20.6% and 16.4% among the married and the unmarried respectively. Results of the Chi-square test show that TB/HIV co-infection was found to be associated with History of the use of TB and HIV drugs defaults, Multiple sex partners, Paid sex, Marital status and occupation of participants. Also, Multiple sex partners (OR = 6.0, 95% CI: 2.4-15.0), Extra-vaginal intercourse (OR= 0.3, 95% CI: 0.1- 0.8) and Paid sex (OR= 0.1, 95% CI: 0.5-0.7) were found to be associated with TB/HIV co-infection among the participants. The study revealed that a higher prevalence of co-infection was observed among 10-49 years age group. This implies that the productive age group bears the brunt of TB/HIV co-infection. It was also found that participants with multiple sex partner (OR=6.01) those whose partners are residing with them(OR=1.45) and those with formal education(OR=1.59) are more likely to have TB/HIV co-infection while those with History of anti-TB drug default(OR=0.54), History of anti-retroviral drug default(OR=0.49), those who practice Extra-vaginal intercourse(OR=0.346) and paid sex(OR=0.19) are less likely to be TB/HIV co-infected. TB/HIV control programs that educate people on the prevalence and focus on these subgroups are likely to decrease the joint burden of TB and HIV

References

Ajayi, B., Moses, A.E., Adelowo, K.and Kudi, A.A.1999. Mycobacteria species from spectrum sample of HIV seropositive and seronegative patient in Maiduguri, Nigeria. Journal of life emotional sciences 4:102-112.
Anne-christine D.June 9,2002. WHO spares down HIV treatment guidelines for poor countries. Retrieved Nov.20,2010 from http ://www. acais. Cornlvubslarnfari 2002 /AM02070l .html.
Anteyi, E. A., Idoko, J. A., Ukoli, C. O., & Bello, C. S. (1996). Clinical pattern of human immunodeficiency virus infection (HIV) in pulmonary tuberculosis patients in Jos, Nigeria. African journal of medicine and medical sciences, 25(4), 317-321.
Bal, A.M., Lakhashe, S. K., Thakar, M. R., Tripathy, S. P. and Paranjape, R.S. 2004. Dysregulation of pro-inflamatory and regulatory cytokins in HIV infected person with active tuberculosis. Cytockine 30: 275-281.
Bass, J.R., Farer, L.S.and Hopewel, P.C. 1990. Diagnostic standards and classification of TB. American Review of Respiratory Diseases142:725-735.
Bello, S.I. 2010. Challenges of DOTS implementation strategy in the treatment of tuberculosis in a tertiary health institution,Ilorin, Nigeria. African Journal of Pharmacy and Pharmacology 4.4:158-164.
Blumberg, H.M., Bunnan, W.J.and Chaissoq, R.E.2003. Treatment of Tuberculosis. America Journal of Respiratory Critical Care Medicine167: 603-662.
Brindle, R.J., Nunn, P.P., Githui, W. 2003. Quantitative bacillary response to treatment in HIV-associated pulmonary TB. American Review in Respiratory Diseases 197:958-961.
British HIV Association.Oct. 6, 2004. BHlVA treatment guidelines for TB/ HIV infection. Retrieved on Dec. 15,2010 from http://www.bhiva.org.
Brooks, G.F., Butel, J.S. and Morse S.A. 2004. Medical microbiology. 23rd ed. New York: McGraw-Hill. 75-100
Centers for Disease Control and Prevention. 1998. Prevention and treatment of TB among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Morbidity and Mortality Weekly Report 47: 1-25.
Centers for Disease Control and Prevention. 2002. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active TB with intermittent rifamycin-based regimens. Morbidity and Mortality Weekly Report 51:214-215.
Centers for Disease Control and Prevention. May,2004. Treating opportunistic Infections Among HIV-Infected Adults and Adolescents. Retrieved on Jan. 6, 2011 from http://www.cdc.gov/mmwr/preview/mmwrhtml;mm53 I5al.htm
Centers for Disease Control and Prevention (CDC. "Decrease in reported tuberculosis cases-United States, 2009." MMWR. Morbidity and mortality weekly report 59.10 (2010): 289.
Cichocki P. June 7, 2007. The history of HIV. Retrieved on Jan. 8,2011from http://aids.about.com on January 2011.
Corbett, E. L., Watt, C. J., Walker, N., Mathew, D. and Williams, C. 2003. The growing burden of tuberculosis: global trends and interactions with the HIV Epidemic. Archeology Intern Med 163:1009-1021.
Corbett E L, Bandason T, Cheung YB, Munyati S, Godfrey-Faussett P, Hayes R, et al. (2007) Epidemiology of Tuberculosis in a High HIV Prevalence Population Provided with Enhanced Diagnosis of Symptomatic Disease. PLoS Med 4(1): e22. https://doi.org/10.1371/journal.pmed.0040022
Datiko , Q. G., Yassin M. A., Chekol L. T., Kabeto L. E. and Lindtjan, B. 2008. The rate of TB-HIV con-infection depends on the prevalence of HIV infection in a community. Biomed Central Public health 8.266:1471-1488. Retrieved on. Dec.12, 2010 from http://www.biomedcentral.can/1471-2458/8/266.
Dauda, M. M. 2010. Evaluation of the efficacy of directly observed treatment shortcaurse in patients with HIV/TB confection in Kano. Reviews in infections 1.5: 218-223.
Deriemer, K., Kawamura, L.M., Hopewelly, P.C. and Daley, C. L. 2007. Quantitative impact of human immunodeficiency virus infection on Tuberculosis dynamics. American Journal of Respiratory critical care medicine 176:936-943.
Ejikeme, N. and Godwin, A.P.2010. Prevalence of Mycobacterium tuberculosis and human immunodeficiency virus (HIV) infections in Umuahia, Abia state, Nigeria. African Journal of microbiology research 4.14:1486 -1490. Retrieved on Feb 10,2011 from http://www.academicjournals.org/ajmr.
El-Sadr, W.M., Perlman, D.C., Denning, P. 2001. A review of efficacy studies of 6-month short course therapy for TB among patients infected with human immunodeficiency virus:differences in study outcomes. Clinical Infectious Disease 32: 623-631.
Ellner, J.J. 2007. The interaction between HIV and Mycobacterium tuberculosis. Opportunistic Infections 197:216 -218.
Erhabor, O., Jeremiah, Z.A., Adias, T.C and Okere C E. 2010. The prevalence of human immunodeficiency virus infection among TB patients in Porthercourt, Nigeria. HIV/AIDS research and palliative care 2: 1-5.
Fauci, A., 1998. Principles of Internal medicine. 14th ed. New York: Mc Graw-Hill:78- 81
Federal Ministry of Heath.2005. 2006-2010 national strategic framework for implementing TB/HIV collaborative activities in Nigeria:7-20
Federal Ministry of Health Nigeria. (2008). Tuberculosis care with TB-HIV Co-management for General health care workers in primary and secondary Health Facilities:10-16
Fitzgerald, D.W., Desvarieux, M. and Severa, P.2000.Effect of post-treatment isoniazid on prevention of recurrent TB in HIV-I-infected individuals: a randomised trial. Lancet 356: 1470- 1474.
Glassroth, J. (2005). Tuberculosis 2004: challenges and opportunities. Transactions of the American clinical and climatological association, 116, 293.
Glynn JR, Warndorff DK, Fine PEM, Msiska GK, Munthali MM, Ponnighaus JM. The impart of HTV on morbidity and mortality from tuberculosis in sub-Saharan Africa: a study in rural Malawi and review of the literature. Health Transition Rev 1997; 7(Suppl 2): 75-87
Glynn H Judith; Resurgence of tuberculosis and the impact of HIV infection. Br Med Bull 1998; 54 (3): 579-593. doi: 10.1093/oxfordjournals.bmb.a011712
Godfrey-Faussett, P., & Ayles, H. (2002). The impact of HIV on tuberculosis control--towards concerted action. Leprosy review, 73(4), 376-85.
Goldfield, A. and Eller, J. J. 2007. Pathogenesis and Management of HIV/TB confection in Asia. Tuberculosis 87:526-530.
Htay, Z. Aug. 10,1999. Management of TB in HIV infected patients. Retrieved on Dec. 15, 2010 from http :// www. dcmsonlinc. org/jax medicine /1999journals /august99/ tb.htm
Herold, C.D., Fitzgerald, R.L. and Herold, D.A.1996. Current techniques in mycobacterial detection and speciation. Critical Reviews in Clinical & Laboratory Sciences 33:83-138.
Hudson, C.P., Wood, R., Martens, G. 2000. Diagnosing HIV-associated TB: reducing cost and diagnostic delay. International Journal of Tuberculosis and Lung Diseases 4:240-245.
Hussain, H., Akhtar, S., & Nanan, D. (2003). Prevalence of and risk factors associated with
Pakistan. International Journal of Epidemiology, 32(5), 794–799. doi:10.1093/ije/dyg247
Hutton,M.D., Stead,W.W., Cauthean, G.M. 1990. Nosocomial transmission of TB associated with a draining abscess. Journal of infectious diseases 161: 286-295.
Idemyor, V. 2007. HIV and Tuberculosis confection: inextricably linked Liason. Journal of the Nigerian Medical Association 99.12: 1415-1419.
Idoko, J., Anteyi, D.E., Agbali, H. and Ibrahim, T. 1994. Human immunodeficiency virus and associated TB in Jos, Nigeria. Journal of Nigeria medical practice 28:148-150.
Ige, O. M., Sogaolu, O. M., & Ogunlade, O. A. (2005). Pattern of presentation of TB and hospital prevalence of TB and HIV co-infection at UCH, Ibadan: a review of 5 years. Afr J Med Sci, 34, 329-33.
Iliyasu, Z., & Babashani, M. (2009). Prevalence and predictors of tuberculosis coinfection among HIV-seropositive patients attending the Aminu Kano Teaching Hospital, northern Nigeria. Journal of epidemiology, 19(2), 81-87.
Juditty, R.G.1998. Resurgence of TB and impact of HIV infection. British Medical bulletin 52.3: 579-593.
Keane, J., Gershon S., Wise R.P., Mirabile E., Kasznica, J., Schwietennan, W.D. 2001. Tuberculosis associated with infliximab, a tumor necrosis factor α - neutralizing agent. The New England Journal of Medicine 345:1098-1104